Lilly’s triple agonist retatrutide posts strongest weight-loss data to date, with unusual sensory skin side effect reported

Eli Lilly; retatrutide; triple agonist; triple hormone receptor agonist; GLP-1; GIP; glucagon; obesity; weight loss; TRIUMPH-4; Phase III; dysesthesia; abnormal sense of touch; safety signal; side effects

Researchers Advance Toward Matching Patients with the Most Effective GLP-1 Drug for Personalized Obesity Treatment

GLP-1; precision medicine; obesity; drug response prediction; genetic test; personalized care; side effects; machine learning; MyPhenome; Mayo Clinic; treatment adherence

Viking Therapeutics Shares Crash After Obesity Pill VK2735 Delivers 12% Weight Loss, But Side Effects and Discontinuations Raise Concerns

Viking Therapeutics; VK2735; obesity pill; weight loss; clinical trial; stock crash; side effects; adverse events; gastrointestinal; drug efficacy

Avalyn Pharma Raises $100M to Advance Inhaled Lung Disease Drugs

Avalyn Pharma; $100 million Series D; inhaled lung disease medications; pulmonary fibrosis; AP01; AP02; pirfenidone; nintedanib; clinical trials; drug safety; side effects; Suvretta Capital Management; SR One; Novo Holdings

Patient suffers side effect in Cabaletta autoimmune CAR-T trial, but analysts unfazed

Systemic Scleroderma, Lupus Erythematosus, Systemic, Cabaletta, cell-associated neurotoxicity, Adverse effects, analysts, Autoimmune Diseases, CAR-T therapy, reSET (device), aspects of adverse effects, Cytokine Release Syndrome

GLP-1 Medications: Balancing Efficacy and Concerns Amidst Celebrity Endorsements and Rising Demand

GLP-1 agonists, Weight loss, Type 2 diabetes, Celebrity endorsements, Side effects, Long-term safety, Cost implications, Employer health plans